[ad_1]
He notes that AstraZeneca can be transported and stored for at least six months under normal cooling conditions of two to eight degrees Celsius. Meanwhile, Pfizer and BioNTech have to store the vaccine at a room temperature of minus 70-80 degrees, which greatly complicates logistics, and poorer countries may simply not have the necessary equipment.
Also, the AstraZeneca vaccine is cheaper than Moderna and Pfizer-BioNTech. Additionally, AstraZeneca also promised to supply the vaccine at a non-commercial price during the pandemic of approximately $ 3 per dose. According to a memorandum of understanding signed between AstraZeneca and the Brazilian vaccine manufacturer, the non-commercial window could be open until mid-2021.
Earlier this month, The Guardian wrote that the COVID-19 vaccine, developed by the American biotech company Moderna, will primarily target the American market for a number of reasons and may not be affordable for poor countries.
“It just came to our attention then. In the summer, Moderna focused on $ 37 per dose, which is significantly more expensive than Johnson & Johnson ($ 10) or Pfizer ($ 20) vaccines, the British newspaper said.
A report by British researchers published last week in the medical journal The Lancet found that AstraZeneca’s vaccine against SARS-CoV-2, COVID-19, had shown good results in patients older than 70 years.
AstraZeneca estimates that the vaccine could be produced in the next year with up to 3 billion euros over the next year if the supervisory authorities approve it. dose of the preparation.
The European Commission has already signed a contract for the supply of COVID-19 with five of its developers – AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica, BioNTech-Pfizer, CureVac – and is preparing to sign a sixth such contract with ” Modern ”.
[ad_2]
